Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of PEG-HM-3 and platinum, taxol or Emtriva medicines to preparation of solid tumor medicines

A technology of PEG-HM-3 and paclitaxel, applied in antitumor drugs, drug combinations, pharmaceutical formulations, etc., can solve the problems of tumor cell drug resistance, complex pathogenesis, difficult to effectively inhibit tumors, and poor effect. , to achieve significant social value and market value, combine drug science, and reduce the effects of toxic and side effects

Inactive Publication Date: 2014-03-12
NANJING ANJI BIOLOGICAL TECH CO LTD
View PDF3 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] For the drugs for the treatment of tumors, because tumor cells have strong drug resistance and the pathogenesis is complex, it is difficult to achieve an effective tumor inhibitory effect by using a certain chemotherapeutic drug alone, and it is necessary to use drugs with different mechanisms in combination to achieve an effective effect. The therapeutic effect of
However, there are interactions between drugs. When drugs with different mechanisms are used in combination, it is necessary to verify whether they can achieve the best therapeutic effect through experiments. If they are not used properly, not only the effect is not good, but also more toxic side effects will occur.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of PEG-HM-3 and platinum, taxol or Emtriva medicines to preparation of solid tumor medicines
  • Application of PEG-HM-3 and platinum, taxol or Emtriva medicines to preparation of solid tumor medicines
  • Application of PEG-HM-3 and platinum, taxol or Emtriva medicines to preparation of solid tumor medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1 Inhibitory effect of PEG-HM-3 combined with oxaliplatin and docetaxel on human lung cancer H460 transplanted tumor in nude mice

[0047] Lung cancer tissues in the vigorous growth stage were taken and ground under sterile conditions, and prepared into 1×10 7 / mL cell suspension, planted in the right armpit of mice with 0.1 mL. When the tumor volume reaches 100mm 3The diameter of the transplanted tumor was measured with a vernier caliper on the left and right, and the anti-tumor effect of the tested animals was dynamically observed. It is administered by tail vein injection or subcutaneous injection, and the dosage regimen is shown in Table 1. Tumor diameters were measured every other day. The administration volume is 0.2ml / only. The negative control was injected with the same volume of saline in the tail vein. After 21 days, the mice were sacrificed, and the tumor mass was removed and weighed. The formula for calculating tumor volume (TV) is:

[0048] T...

Embodiment 2

[0064] Embodiment 2 The inhibitory effect of PEG-HM-3 combined with oxaliplatin and Xeloda on human liver cancer SMMC-7721 transplanted tumor in nude mice

[0065] Liver cancer tissues in vigorous growth phase were taken and ground under sterile conditions, and prepared into 1×10 7 / mL cell suspension, planted in the right armpit of mice with 0.1 mL. Others participate in Example 1.

[0066] The test was divided into 7 groups, PEG-HM-3 group with 8 rats in each group, other treatment groups with 10 rats in each group, and control group with 13 rats. See Table 3 for the specific dosage regimen.

[0067] Table 3 Administration Settings

[0068]

[0069] Tumor weight (g) and tumor inhibition rate (%) when table 4 was treated on the 21st day

[0070]

[0071] The data analysis software was SPSS, and the average tumor weight of each group was expressed as mean±SD. According to the T test, the tumor inhibition rate was calculated = (tumor weight of the negative group - tum...

Embodiment 3

[0076] Example 3 PEG-HM-3 Combined with Docetaxel, Oxaliplatin Inhibitory Effect of Human Breast Cancer MDA-MB-231 Nude Mice Transplanted Tumors

[0077] Breast cancer tissues in vigorous growth stage were taken and ground under sterile conditions, and prepared into 1×10 7 / mL cell suspension, planted in the right armpit of mice with 0.1 mL. Other model preparation methods are referring to embodiment 1.

[0078] The experiment was divided into 8 groups, 12 rats in the negative control group, 8 rats in the PEG-HM-3 group, and 10 rats in each other treatment group. See Table 1 in Example 1 for the specific dosage regimen. After the 21st day of treatment, the nude mice were dissected, tumors were taken, and the tumor inhibition rate was determined.

[0079] Table 5 tumor weight (g) and tumor inhibition rate (%)

[0080]

[0081] The data analysis software was SPSS, and the average tumor weight of each group was expressed as mean±SD. Tumor inhibition rate=(tumor weight in ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of PEG-HM-3 and platinum, taxol or Emtriva medicines to preparation of solid tumor medicines, and belongs to the field of medicines for treating tumors. The PEG-HM-3 is polyethylene glycol modified polypeptide HM-3 with the molecular weight range of 10,000 to 40,000; and the platinum, taxol or Emtriva medicines serving as active components and auxiliary acceptable medicinal carriers are prepared into various pharmaceutically acceptable preparations. According to a large amount of experiments, an integrin blocking agent PEG-HM-3 has a definite target spot and is reasonably used in combination with platinum, taxol or Emtriva, so growth of tumors such as lung cancer, liver cancer, gastric cancer, breast cancer, cervical cancer, ovarian cancer and intestinal cancer can be effectively inhibited. The medicines are combined to serve as a medicine, so tumors can be treated effectively, medicine combination is scientific, reasonable, practical and effective, the treatment spectrum of tumor treatment is greatly enlarged, the toxic or side effect is reduced, and obvious social value and market value are achieved.

Description

technical field [0001] The invention relates to the field of drugs for treating tumors, more specifically, the application of PEG-HM-3 and platinum, paclitaxel or tabine anti-metabolite drugs in the preparation of solid tumor drugs. Background technique [0002] Tumor is a complex disease, and it is difficult to achieve the desired therapeutic effect by using a single drug. Currently, a combination of drugs is often used for clinical treatment. The advantage of combination drug in tumor treatment is to enhance the curative effect, reduce the occurrence of adverse reactions, and prevent the tumor from developing drug resistance. Rational drug combination based on the mechanism of action of antineoplastic drugs is one of the important advances in chemotherapeutic drug therapy in recent years. Combination of antineoplastic drugs with different mechanisms of action can often enhance the efficacy. Combining alkylating agents (such as cyclophosphamide or carmustine) that damage ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K47/48A61P35/00A61K31/7068A61K31/706A61K31/555A61K31/337A61K33/24A61K31/282
Inventor 徐寒梅
Owner NANJING ANJI BIOLOGICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com